# The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes

Study · id `cardio:ct-nct05566028` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05566028](<https://clinicaltrials.gov/study/NCT05566028>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05566028

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 172 participants.

## Technical summary

Registry record NCT05566028. Randomized; double masking; primary purpose treatment. Start 2022-10-12 (actual); primary completion 2024-01-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 172 participants (enrolled count; ClinicalTrials.gov record NCT05566028, source copy `cardio:ctgov-nct05566028-2024-12-10`, retrieved 2026-10-26)
- Started: 2022-10-12 (actual) (ClinicalTrials.gov record NCT05566028, source copy `cardio:ctgov-nct05566028-2024-12-10`, retrieved 2026-10-26)
- Primary completion: 2024-01-10 (actual) (ClinicalTrials.gov record NCT05566028, source copy `cardio:ctgov-nct05566028-2024-12-10`, retrieved 2026-10-26)
- Completion: 2024-07-23 (actual) (ClinicalTrials.gov record NCT05566028, source copy `cardio:ctgov-nct05566028-2024-12-10`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05566028, source copy `cardio:ctgov-nct05566028-2024-12-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05566028-2024-12-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): D745 formulation I
- Intervention (Drug): D745 formulation II
- Intervention (Drug): D745 Placebo
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: fc82da21715335383d186ba21f69e9ee534d903e22a49d7f2a1a296337069727
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
